Verona Pharma plc (VRNA)

Market Cap	7.92B
Revenue (ttm)	118.54M
Net Income (ttm)	-163.94M
Shares Out	91.14M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	57.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,360,728
Open	91.01
Previous Close	91.20
Day's Range	86.63 - 91.72
52-Week Range	15.80 - 99.01
Beta	0.24
Analysts	Strong Buy
Price Target	112.56 (+29.59%)
Earnings Date	Aug 7, 2025

About VRNA

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 27, 2017
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: VRNA
• Website: https://www.veronapharma.com

Analyst Summary

According to 9 analysts, the average rating for VRNA stock is "Strong Buy." The 12-month stock price target is $112.56, which is an increase of 29.59% from the latest price.

Price Target

$112.56

(29.59% upside)

Analyst Consensus: Strong Buy